Wednesday 18 April 2018

Reuters Health Report: Novo Nordisk, Red Cross team up to tackle chronic diseases in conflict zones

Novo Nordisk, Red Cross team up to tackle chronic diseases in conflict zones

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk and aid agency Red Cross have teamed up to try to improve the treatment of chronic diseases among the millions affected by conflicts and humanitarian crises in countries such as Syria and Yemen.

U.S. drug agency proposes rules to rein in opioid manufacturing

WASHINGTON (Reuters) - The U.S. government on Tuesday proposed tightening rules governing the amount of prescription opioid painkillers that drugmakers can manufacture in a given year, in hopes of reining in the deadly opioid epidemic.

Canada seeks U.S. help to solve EpiPen shortage

TORONTO (Reuters) - Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States.

Global leaders seek to reignite fight against deadly malaria

LONDON, April 18 (Reuters) - Renewed action and boosted funding to fight malaria could prevent 350 million cases of the disease in the next five years and save 650,000 lives across commonwealth countries, health experts said on Wednesday.

Royal wedding obsession: fun can deepen to mental health problem

NEW YORK (Reuters) - Fans of the British royals have been awash in glittering titillation over the upcoming nuptials of Prince Harry and American actress Meghan Markle, but counselors warn there is a dark side: extreme and potentially dangerous obsession.

J&J raises sales forecast but keeps profit outlook unchanged; shares drop

(Reuters) - Johnson & Johnson raised its sales forecast for the year on Tuesday but kept its outlook for full-year profit unchanged, disappointing investors and sending its shares down 1.6 percent.

GE rides gene therapy wave with ready-made viral drug factories

LONDON (Reuters) - General Electric is raising its bet on biotechnology with the launch of prefabricated manufacturing units for producing virus-based gene and cell therapies, novel anti-cancer treatments and vaccines.

Amgen's Aimovig halved migraine days in 30 percent of trial patients

LOS ANGELES (Reuters) - A late-stage trial of Amgen Inc's experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.

UnitedHealth earnings ease investor worries over flu season, stock up

(Reuters) - UnitedHealth Group Inc , the largest U.S. health insurer, on Tuesday reassured investors that the pervasive flu season did not crimp first-quarter earnings as had been feared, boosting its shares as well as those of rivals.

Marijuana-related ER visits by Colorado teens on the rise

(Reuters Health) - More visits to the emergency room by teens in Colorado are related to marijuana use than in the past, suggesting an impact of the drug's legalization that needs closer attention, researchers say.

Related Videos

Plastic-eating enzyme holds promise in fighting pollution - scientists

'Urban mining' in S.Korea pulls rare battery materials from recycled tech

You might like...

Check out our Reuters News Now daily briefing for hand-picked stories from Reuters editors. It's all the news you need to start your day.

Subscribe here